Document is current

Article History

Received: 3 February 2025

Accepted: 16 June 2025

First Online: 9 July 2025

Declarations

:

: Ovidio Fernández has received support for the present manuscript from Merck, fees for consultant or honoraria from Astellas, BMS, Janssen, Merck, MSD, Novartis, Recordatti, Roche, and Triple A; travel support from Ipsen, and Merck; has a leadership role in SOGUG. Aurea Molina has received honoraria from BMS, Eisai, Grünenthal Pharma, Ipsen, Kyowa Kirirn, Merck, Pharmamar, and Roche; travel support from Astellas, Astra Zeneca, BMS, Eisai, Kyowa Kirirn, Lilly, Merck, MSD, Pfizer, Pharmamar, Pierre Fabre, Roche, Sanofi, and Takeda; participation on Advisory Boards from Bayer, Eisai, Pfizer, Pharmamar, and Pierre Fabre. Urbano Anido-Herranz has received fees for consultant or advisory board from Advanced Accelerator Applications, Astellas, Astra Zeneca, Bayer, BMS, GSK, Ipsen, Merck, MSD, and Pfizer; travel support from Advanced Accelerator Applications, Bayer, Ipsen, Merck, Pfizer, Roche, and Sanofi; and honoraria from Advanced Accelerator Applications, Astra Zeneca, BMS, Eisai, Grünenthal Pharma, Ipsen, Leo Pharma (an immediate family member), Merck, and Rovi. Carlos Alvarez has received honoraria from Astra Zeneca, Bayer, and Pfizer; travel support from Ipsen, Pfizer, and Roche. Regina Gironés has received fees for speaker or expert testimony from Astellas, Astra Zeneca, Bayer, BMS, Ipsen, Janssen, Merck, MSD, Noartis, Novocure, Pfizer, and Roche; travel support from Astra Zeneca, Bayer, Novartis, and Pfizer. Pablo Gajate has received fees for advisory/consultancy roles or speaker from AAA, Astellas, Bayer, Bristol-Myers-Squibb, Eisai, Ipsen, Janssen, Merck, MSD, Pfizer, Roche, and Sanofi. Silverio Ros has received honoraria from Bayern, Bristol Mayer, and Roche; fees for expert testimony from Bristol Mayer, Roche, and Sanofi; travel support from Ipsen, Merck, and Pierre Fabre; participation on Advisory Boards from Bristol Mayer, and Roche. Javier Puente has received fees for consultancy from Gilead, Pfizer and Roche; honoraria for lectures from Astra Zeneca, BMS, Eisai, Janssen, Merck, MSD, and Pfizer; travel support from Janssen, Merck, and Pfizer; participation on Advisory Boards from Astra Zeneca, BMS, Gilead, Janssen, Merck, MSD, and Pfizer. Sara Blasco has received grants or honoraria from Merck; travel support from BMS. Nieves del Pozo has received travel support from posESMO GU. Martín Lázaro Quintela has received fees for speaker or expert testimony from Amgen, Astellas, Astra Zeneca, Bayer, BMS, Ipsen, Merck, MSD, Olpsen, Pfizer, and Roche; travel support from Ipsen, MSD, Roche and Takeda. Guillermo Crespo has received fees for consultancy and honoraria from Astellas, BMS, Esteve, Ipsen, Janssen, Merck, MSD, Novartis, and Sanofi; travel support from BMS, Esteve, Ipsen, Janssen, Merck, MSD, and Novartis. Alfredo Sánchez-Hernández has received honoraria from Astra Zeneca, BMS, Janssen, Lilly, Merck, MSD, Novartis, Pfizer, Roche, Sanofi, and Takeda; travel support from BMS, Janssen, MSD, Pfizer, Roche, Sanofi, and Takeda. María José Juan has received support for the present manuscript from Merck; fees for consultancy or honoraria from Astellas, Astra Zeneca, Bayer, Johnson and Johnson, Ipsen, MSD, and Pfizer; travel support from Bayer, Johnson and Johnson, Ipsen, and MSD; participation on Advisory Boards from Bayer, Ipsen, and MSD. Rocío García Domínguez, Martín Oré-Arce, Esther Noguerón Martínez, Ana Fernández-Freire, Javier Casinello, Fernando Arranz, María Teresa Abad, and Mar Llorente have declared no conflict of interest.

: Research approval was obtained from the corresponding Research Ethic Committee for medicinal products (CEIm) where centers are located.

: The informed consent was obtained from all patients.